TABLE 3.
Clinical outcomes at baseline, end of treatment (12 weeks), and wash‐out period (16 weeks) comparing bosutinib and placebo
| Changes | Clinical endpoints | Bosutinib vs. placebo | P‐value Wilcoxon |
|---|---|---|---|
| 12 week‐ baseline | Montreal Cognitive Assessment (MoCA) | 0 (−1, 2) | 0.773 |
| Trail Making Test (TMT)‐Part B | −43 (−113, 22) | 0.151 | |
| Timed Up and Go | 0 (−3, 2) | 0.725 | |
| Unified Parkinson's Disease Rating Scale (UPDRS‐Cognition)‐Part I | 0 (−2, 1) | 0.795 | |
| Unified Parkinson's Disease Rating Scale (Activities of Daily Living)‐Part II | −1 (−3, 2) | 0.622 | |
| Unified Parkinson's Disease Rating Scale (Motor)‐Part III | 0 (−4, 4) | 0.938 | |
| Unified Parkinson's Disease Rating Scale (SUM Part II+III) | −1 (−6, 5) | 0.738 | |
| Unified Parkinson's Disease Rating Scale (total Part I+III) | −2 (−7, 6) | 0.777 | |
| Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS‐Cog) | −0.66 (−4.67, 3.33) | 0.817 | |
| Irritability and Apathy Scale (IAS)‐_Partner_APATHY | −1 (−4, 2) | 0.571 | |
| Irritability and Apathy Scale (IAS)‐_Participant_APATHY | 0 (−3, 4) | 0.836 | |
| Irritability and Apathy Scale (IAS)‐_Partner_IRRITABILITY | 1 (−1, 4) | 0.255 | |
| Irritability and Apathy Scale (IAS)‐_Participant_IRRITABILITY | 0 (−2, 3) | 0.777 | |
| Alzheimer's Disease Cooperative Study‐Activities of Daily Living (ADCS‐ADL) | −5 (−8, 0) | 0.037 | |
| Neuropsychiatric Inventory (NPI) frequency x severity | 0 (−8, 9) | 0.939 | |
| Neuropsychiatric Inventory (NPI)_Caregiver Distress | 2 (−1, 6) | 0.127 | |
| Problem Behaviours Assessment (PBA) | 1 (−14, 10) | 0.898 | |
| Clinician Assessment of Fluctuation (CAF) | 1 (−2,3) | 0.378 | |
| 16 week‐ baseline | Montreal Cognitive Assessment (MoCA) | 1 (−1, 3) | 0.234 |
| Trail Making Test (TMT)‐Part B | −25 (−74, 20) | 0.27 | |
| Timed Up and Go | 0 (−2, 1) | 1 | |
| Unified Parkinson's Disease Rating Scale (UPDRS‐Cognition)‐Part I | −1 (−2, 1) | 0.328 | |
| Unified Parkinson's Disease Rating Scale (Activities of Daily Living)‐Part II | 0 (−2, 2) | 0.815 | |
| Unified Parkinson's Disease Rating Scale (Motor)‐Part III | −3 (−9, 2) | 0.193 | |
| Unified Parkinson's Disease Rating Scale (SUM Part II+III) | −3 (−9, 3) | 0.271 | |
| Unified Parkinson's Disease Rating Scale (total Part I+III) | −4 (−10, 2) | 0.165 | |
| Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS‐Cog) | −4.67 (−10.34, 1) | 0.111 | |
| Irritability/Apathy Scale (IAS)‐_Partner_APATHY | 0 (−4, 4) | 0.836 | |
| Irritability/Apathy Scale (IAS)‐_Participant_APATHY | 0 (−4, 3) | 0.918 | |
| Irritability/Apathy Scale (IAS)‐_Partner_IRRITABILITY | 1 (−3, 5) | 0.553 | |
| Irritability/Apathy Scale (IAS)‐_Participant_IRRITABILITY | −2 (−4, 0) | 0.07 | |
| Alzheimer's Disease Cooperative Study‐Activities of Daily Living (ADCS‐ADL) | −2 (−8, 5) | 0.837 | |
| Neuropsychiatric Inventory (NPI) frequency x severity | 2 (−6, 10) | 0.608 | |
| Neuropsychiatric Inventory (NPI)_Caregiver Distress | 3 (−2, 8) | 0.142 | |
| Problem Behaviours Assessment (PBA) | 2 (−7, 11) | 0.589 | |
| Clinician Assessment of Fluctuation (CAF) | 1 (−1, 3) | 0.288 |